Versantis has closed a series B financing round, and plans to use the funds to fuel the completion of ongoing Phase 1b studies with VS-01 and advance its clinical development up to clinical proof-of-efficacy (phase 2a) in 2 indications.
Promethera Biosciences’ Interim safety results and early efficacy signals with HepaStem bodewell for subsequent confirmatory trials in ACLF and provide valuableinsights for imminent start of clinical evaluation in NASH
The U.S. Food and Drug Administration has approved AkaRx’s Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. This is the first drug approved by the FDA for this use.
Boston-based Albireo Pharma, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, has completed its public offering of 1,970,000 shares of its common stock at a price to the public of $33.00 per share.
Tiziana Life Sciences, a clinical stage biotechnology company developing targeted drugs for cancer, autoimmune and inflammatory diseases, has appointed Dr. Arun Sanyal as a new member of its Scientific Advisory Board.
Novartis and Conatus Pharmaceuticals have signed a multipurpose deal which will help the two drug makers to make liver-disease treatment, emricasan.
U.S. Food and Drug Administration (FDA) has given green light to Cerenis Therapeutics to proceed with CER-209 clinical trial.